DOCSLIB.ORG

The Road from Genomics to Personalized Medicine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Road from Genomics to Personalized Medicine The road from genomics to personalized medicine Raeka Aiyar EMBL [email protected] Steinmetz Group Genome Biology Unit EMBL Heidelberg EUSJA Visit, 18 July 2011 www.embl.de/research/units/genome_biology/steinmetz 6 billion base pairs, 22K protein-coding genes, ~300K proteins ~6 million diferences between two individuals Understanding Understanding Understanding Advancing Improving the the structure of the biology of the biology of the science of effectiveness of genomes genomes disease medicine healthcare 1990-2003 Human Genome Project 2004-2010 2011-2020 Beyond 2020 Green, ED et al. Charting a course for genomic medicine from base pairs to bedside. Nature (2011) Personalized/P4 Medicine • Predictive - development of probabilistic health projection based on individual DNA and gene expression • Preventative - creation of therapeutics that will prevent a disease a person is at risk of developing • Personalized - treating an individual based on their unique human genetic variation, complementing the predictive and preventative efforts above • Participatory - patient's active, informed involvement in their medical choices and care, acting in partnership with their health providers The success of genomics Genomic achievements since the Human Genome Project Southern African genome sequences First personal genome Rhesus macaque NCBI's Database of Genotypes and sequenced using new technologies genome sequence Completion of the Mammalian Phenotypes (dbGaP) launched Gene Collection (MGC) 500th genome-wide 9 10 11 12 Phase I HapMap 3 6 7 8 association study 4 5 1 Watson & Crick 2 published describe the DNA double helix 19 21 Y 20 22 16 18 Chicken genome 15 17 !953 13 14 sequence X Human genetic variation is Mendel discovers Yoruba genome breakthrough of the year UK Biobank reaches laws of genetics !966 CFH sequence Age-related macular 500,000 participants !865 degeneration Nirenberg, 1 Khorana & Honeybee Holley determine First genome-wide genome sequence the genetic code association study International data release workshop >1,000 mouse published knockout mutations !977 Wellcome Trust Case Control GA T C Rat genome Consortium publication sequence Platypus genome sequence !982 Sanger and modENCODE publications Maxam & Gilbert develop DNA !990 GenBank sequencing methods database established Human Genome Project Chimpanzee genome Sea urchin launched sequence genome sequence Bovine genome sequence Neanderthal genome sequence !996 ENCODE pilot project complete First cancer genome sequence (AML) Publication of "nished Yeast humanhuman genomegenome sequence (Saccharomyces cerevisiae) genome sequence 2004 !998 Roundworm 1000 Genomes pilot project DogDog genomegenom sequence (Caenorhabditis elegans) First personal genome sequenced complete genome sequence !997 Comprehensive genomic First human methylome map Escherichia coli genome 2005 sequence First direct-to-consumer analysis of glioblastoma wwhole-genomeh test Moore’s law 1 2 3 4 5 6 78 9 2000 Miller syndrome gene discovered by Fruit!y Coding 2006 exome sequencing (Drosophila melanogaster) UTR genome sequence c.56G>A Han Chinese c.403C>Tc.454G>A c.595C>Tc.605A/Cc.611delTc.730C>Tc.851C>T c.1036C>Tc.1175A>G genomege sequence 2003 Cost per human genome sequence 2010 2008 Genetic Information 2006 2007 200! 2004 Nu#eld Council on Bioethics 2002 NondiscriminationNondiscrim Act (GINA) 2002 passedpa in US publication on For details, see http://genome.gov/sequencingcosts 2008 Korean genome sequence personalized healthcare Draft human End of the Human genome sequence Mouse genome Genome Project sequence 2009 Design by Darryl Leja (NHGRI, NIH). 20!0 Watson and Crick photograph: A. Barrington Brown/Photo Researchers; images of Science covers courtesy of AAAS. © 2011 Macmillan Publishers Limited. All rights reserved Green, ED et al. Charting a course for genomic medicine from base pairs to bedside. Nature (2011) The evolution of sequencing technology 300 The Trace archive, started in 2000, houses raw sequence data, and currently holds 1.8 trillion base pairs. Trace $10, 000 250 454 PYROSEQUENCING : Released in 2005, 454 sequencing is considered the first ‘next-generation’ C technique. A machine could sequence ost p er million ba hundreds of millions of base pairs in a se pairs of sequ ence (log scale) single run. 200 AUTOMATED SANGER SEQUENCING: Based on a decades-old method, at the peak of the technique, a single machine could produce hundreds of thousands of base pairs in a single run. $1, 000 150 SEQUENCING BY SYNTHESIS: Other companies such as Solexa (now Illumina) modified the next-generation, sequencing-by-synthesis techniques $100 and can produce billions of base pairs Billions of base pairs in a single run. 100 THIRD-GENERATION SEQUENCING: Companies such as Helicos BioSciences already read sequence from short, single DNA molecules. Others, such as Pacific Biosciences, Oxford Nanopore and Ion Torrent say they can read from longer molecules as they pass through a pore. 50 SEQUENCING BY LIGATION: $10 Whole Genome Shotgun Sequence This technique employed in SOLiD and chemistry from previous technologies Gene sequence stored in and samples every base twice, reducing the error rate. international public databases $1 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Human genome at ten: The sequence explosion. Nature (2010) What would you do if you could sequence everything? Temporal Populations changes Mutation discovery & profiling Protein-DNA Copy number interactions variation Tissue types Environmental & substructures exposures Transcriptionally DNA bar codes active sites AGACCGGC AGTTCCGG GGATCGCG AGTTCCGG CGAGGATG AGACCGGC Metagenomic Compound & heterogeneous libraries samples mRNA microRNA expression expression & discovery & discovery AAAAAAAA AAAAAAAA A Alternative AAAAAAA AAAAAAAA AAAAAAAA splicing & allele-specific expression Kahvejian A et al., Nature Biotechnology (2008) Complex diseases • Do not follow Mendelian inheritance and result from multiple alleles and environment • Responsible alleles contribute different amounts to phenotype • Alleles may be present in only a fraction of all individuals with the phenotype • Need large sample sizes and high density marker maps to find alleles Peltonen, L & McKusick, V. SCIENCE Online 2001 Understanding the biology of genomes Most of the genome is transcribed Pervasive transcription covers: Zhenyu Xu • 70% of human/ mammalian genomes (Carninci et al. 2005) Wu Wei • 85% of yeast genome (David et al. 2006) Julien Gagneur Gingeras, TR. Origin of phenotypes: genes and transcripts. Genome Research (2007) Sandra Clauder-Münster Bidirectional promoters generate pervasive transcription d1 d2 • >30% of promoters are bidirectional, accounting for >50% of unannotated transcripts in the genome Xu, Z., Wei, W., Gagneur, J., Perocchi, F., Clauder-Muenster, S., Camblong, J., Guffanti, E., Stutz, F., Huber, W. and Steinmetz, L.M. Bidirectional promoters generate pervasive transcription in yeast. Nature 2009. Neil, H., Malabat, C., d’Aubenton-Carafa, Y., Xu, Z., Steinmetz, L.M. and Jacquier, A. Widespread bidirectional promoters are the major source of cryptic unstable transcripts in yeast. Nature 2009. Promoter bidirectionality is universal a Yeast Promoter region CUTs and SUTs mRNA Long RNAs Long –2 kb –1 kb Gene DNA b Mammals PALRs PROMPTs mRNA Long RNAs Long –2 kb –1 kb Gene Non-capped: TSSa-RNAs Capped: PASRs Short RNAs NRO-RNAs Carninci, Nature (2009) Yeast: Xu, Z. et al., Bidirectional promoters generate pervasive transcription in yeast. Nature Jan. 2009 Neil, H. et al., Widespread bidirectional promoters are the major source of cryptic transcripts in yeast. Nature Jan. 2009 Human: Leighton, J. et al., Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. Science Dec. 2008 Preker, P. et al., RNA exosome depletion reveals transcription upstream of active human promoters. Science Dec. 2008 He, Y. et al., The antisense transcriptomes of human cells. Science Dec. 2008 Mouse: Seila, A.C. et al., Divergent transcription from active promoters. Science Dec. 2008 Parasites: Teodorovic et al., Bidirectional transcription is an inherent feature of Giardia lamblia promoters and contributes to an abundance of sterile antisense transcripts throughout the genome. Nucleic Acids Res. 2007 Regulatory roles of antisense expression • Transcription interference: • IME4 (Hongay et al., 2006) • Inactivating histone modification: • Pho84 (Camblong et al., 2007) • Ty1 (Berretta et al., 2008) • Gal1-10 (Houseley et al., 2008) • Activating: • Pho5 (Uhler et al., 2007) ORFs with antisense are more often ‘switched off’ 25)ï7VZLWKRXWDQWLVHQVHORFs without antisense 25)ï7VZLWKDQWLVHQVHORFs with antisense 0.30 Density 0.10 0.00 ï 0 4 6 Minimal expression levels across segregants 18% of ORFs with antisense are switched off vs. 8% without Xu Z et al. Antisense expression increases gene expression variability and locus interdependency. Mol Sys Biol (2011) Ultrasensitivity model for antisense function Off state On state TF antisense sense expression regulatory signal -> sense promoter -> sense activation Functional classes of genes with antisense transcripts: cell fate decision genes (e.g. IME4) condition-specific genes: plasma membrane and stress response genes Understanding the biology of Non-coding transcription: Summary genomes TF • Pervasive transcription originates from bidirectional promoters • Antisense transcripts in yeast play a regulatory role in switching genes off • Increase sensitivity to genetic and environmental changes • Beneficial
Load more

Recommended publications
  • Preparing Pathology for Personalized Medicine: Possibilities for Improvement of the Pre-Analytical Phase
    Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase. Patricia Jta Groenen, Willeke A Blokx, Coos Diepenbroek, Lambert Burgers, Franco Visinoni, Pieter Wesseling, Han van Krieken To cite this version: Patricia Jta Groenen, Willeke A Blokx, Coos Diepenbroek, Lambert Burgers, Franco Visinoni, et al.. Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase.. Histopathology, Wiley, 2011, 59 (1), pp.1. 10.1111/j.1365-2559.2010.03711.x. hal-00630795 HAL Id: hal-00630795 https://hal.archives-ouvertes.fr/hal-00630795 Submitted on 11 Oct 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Histopathology Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase. For Peer Review Journal: Histopathology Manuscript ID: HISTOP-08-10-0429 Wiley - Manuscript type: Review Date Submitted by the 06-Aug-2010 Author: Complete List of Authors: Groenen, Patricia; Radboud University Nijmegen Medical Centre, Pathology Blokx,
    [Show full text]
  • IMRE BARTOS Associate Professor of Physics | University of Florida | People.Clas.Ufl.Edu/Imrebartos
    IMRE BARTOS Associate Professor of Physics | University of Florida | people.clas.ufl.edu/imrebartos RESEARCH INTEREST Gravitational wave astrophysics, multi-messenger astrophysics, high-energy astroparticle physics, black hole and neutron star evolution and interactions, cosmology. EDUCATION AND TRAINING Columbia University Physics (Szabolcs Marka) PhD 2012 Eotvos University, Hungary Physics Diploma 2006 PROFESSIONAL APPOINTMENTS Associate Professor University of Florida 2021—present Assistant Professor University of Florida 2017—2021 Associate Research Scientist Columbia University 2016—2017 Lecturer in Discipline Columbia University 2012—2016 HONORS AND AWARDS Alfred P. Sloan Foundation Research Fellowship 2020—2022 Excellence Award for Assistant Professors, University of Florida 2020 Columbia Science Fellow, Columbia University 2012—2016 Allan M. Sachs Teaching Award 2011 Columbia Presidential Teaching Award, Finalist 2012 National Science Foundation Highlights 2014 AAS Nova Highlight 2016 5 Favorite Features of the year, Physics World 2018 Brookhaven National Lab Distinguished Lecture 2016 Rising Stars of Science: The Forbes 30 Under 30 (Forbes Magazine) 2012 Summer Undergraduate Research Fellowship, Caltech 2004 As a member of the LIGO Scientific Collaboration: Special Breakthrough Prize in Fundamental Physics 2016 Gruber Cosmology Prize 2016 Princess of Asturias Award for Technical and Scientific Research 2017 Einstein Medal from the Einstein Society in Bern, Switzerland 2017 Bruno Rossi Prize 2017 Science’s Breakthrough of the
    [Show full text]
  • Kyung Ha Lee
    Kyung Ha Lee Phone: +82-31-290-7042, Email: [email protected] Academic Activities Sungkyunkwan University, Department of Physics, Suwon, South Korea Assistant Professor Sep. 2020 – Present Relevant Area of Science: Gravitational Wave Research (LIGO) Stanford University, Applied Physics, California, United States Postdoc in Applied Physics Feb. 2019 – Aug. 2020 Research Group: Ginzton Laboratory, Martin Fejer Group Relevant Area of Science: Gravitational Wave Research (LIGO) University of Glasgow, School of Physics and Astronomy, Glasgow, United Kingdom Ph.D. in Physics Oct. 2014 – Jan. 2019 Research Group: Institute for Gravitational Research (IGR) Relevant Area of Science: Gravitational Wave Research (LIGO) Seoul National University, School of Physics and Astronomy, Seoul, South Korea Researcher Jun. 2012 – May. 2013 Research Group: RENO Collaboration Relevant Area of Science: Neutrino Oscillation Experiment California Institute of Technology (Caltech), Department of Physics, Pasadena, CA. USA B.S. in Physics with Honor Oct. 2007 – Jun. 2011 Relevant Area of Science: Gravitational Wave Research (LIGO) Awards and Scholarship - Scottish Universities Physics Alliance (SUPA) Prize Studentship (2014) o This studentship is for 3.5 years and provides annual maintenance allowance, annual RTSG (Research Training Support Grant), and full cost of university tuition fees. - Thomson Experimental Prize (2017) o This prize was founded in 1869 by William Thomson later created 1st Baron Kelvin. It is awarded on the recommendation of the Professor of Natural
    [Show full text]
  • Personalized Medicine: Definitions, History, and Implications for the OT Profession
    The Open Journal of Occupational Therapy Volume 3 Issue 4 Fall 2015 Article 1 October 2015 Personalized medicine: Definitions, history, and implications for the OT profession Diane Powers Dirette Western Michigan University - USA, [email protected] Follow this and additional works at: https://scholarworks.wmich.edu/ojot Part of the Occupational Therapy Commons Recommended Citation Dirette, D. P. (2015) "Personalized medicine: Definitions, history, and implications for the OT profession," The Open Journal of Occupational Therapy: Vol. 3: Iss. 4, Article 1. Available at: https://doi.org/10.15453/ 2168-6408.1213 This document has been accepted for inclusion in The Open Journal of Occupational Therapy by the editors. Free, open access is provided by ScholarWorks at WMU. For more information, please contact wmu- [email protected]. Personalized medicine: Definitions, history, and implications for the OT profession Keywords individualized medicine, personalized medicine, precision medicine, stratified medicine, paradigm shifts Credentials Display Diane Powers Dirette, Ph.D., OTL Copyright transfer agreements are not obtained by The Open Journal of Occupational Therapy (OJOT). Reprint permission for this Letter from the Editor should be obtained from the corresponding author(s). Click here to view our open access statement regarding user rights and distribution of this Letter from the Editor. DOI: 10.15453/2168-6408.1213 This letter from the editor is available in The Open Journal of Occupational Therapy: https://scholarworks.wmich.edu/ ojot/vol3/iss4/1 Dirette: Personalized medicine in OT That dreaded phone call comes from your treatment of leukemia, cystic fibrosis, liver cancer physician in the middle of the day informing you of (Kaiser, 2015), lung cancer (Eisenstein, 2014), the results of your biopsy that was ordered amyotrophic lateral sclerosis (Cashman & Ospri, following an abnormal mammogram.
    [Show full text]
  • Personalized Medicine: the Impact of Molecular Testing on Patient Care
    Personalized Medicine: The Impact of Molecular Testing on Patient Care Mini-Elective Spring 2020 University Course Dates: January 17, 24, 31, February 7, 14 Fridays, 2:30-4:30 PM of Pittsburgh Maximum Students: 5 School of Class Year: MS1 and MS2 Medicine Course Directors: Simion Chiosea, MD Professor of Pathology Somak Roy, MD Assistant Professor of Pathology Contact Information: Lynn Wolkenstein 412-647-7065 [email protected] Jessica Tebbets 412-802-6797 [email protected] Registration: Betsy Nero, Office of Medical Education [email protected] Description: Personalized medicine applies knowledge of molecular data for early disease detection, targeted treatment, and detection of person’s predisposition to a particular disease. It improves diagnosis and treatment of a disease and advances effectiveness of healthcare. This mini-elective is based in the Department of Pathology and will introduce students to principles and current applications of personalized medicine. During mini-elective students will be able to observe and discuss the principles of molecular testing, become familiar with the clinical interpretation of molecular results in all areas of medicine, including oncology, neuro-oncology, endocrinology, and gastroenterology. The training will be conducted in the clinical Molecular and Genomic Pathology (MGP) laboratory, Department of Pathology, University of Pittsburgh. MGP laboratory is one of the largest laboratories in the US focused on molecular diagnostics of solid tumors. It processes over 22,000 samples each year using high-throughput technologies, such as Next Generation Sequencing (NGS) and a variety of the conventional molecular biology techniques. It performs molecular testing for all hospitals of the UPMC system and serves as reference laboratory for other medical centers across the United States.
    [Show full text]
  • New Contract Award
    TRI-Supported Trial Named Science Magazine’s 2011 “Breakthrough of the Year” Bethesda, Maryland (May 18, 2012): Technical Resources International, Inc. (TRI) is proud to have provided regulatory, safety, and technical support to the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), NIH for the HIV clinical trial that was chosen as the 2011 Breakthrough of the Year by Science Magazine. The NIAID-sponsored HPTN 052 study was an international HIV prevention trial conducted in nine countries. Investigators conducting the study reported that HIV-infected heterosexual individuals who began taking antiretroviral medicines when their immune systems were relatively healthy were 96 percent less likely to transmit the virus to their uninfected partners. Federal officials and the medical community are advocating a ‘treatment-as-prevention’ approach be included as a key component of public health policies due in large part to the results of HPTN 052. They also indicate these findings will have positive implications in domestic and public health in the coming years and even suggest that achieving an end to the HIV/AIDS pandemic is now feasible. About NIAID: NIAID is working to end the HIV/AIDS epidemic by advancing basic knowledge of the pathogenesis and transmission of HIV, supporting the improvement of therapies for HIV infection and its complications, and supporting the development of HIV/AIDS vaccines and other prevention measures. NIAID sponsors Phase I, II, III and IV clinical trials to assess the safety and efficacy of therapeutics, vaccines, and other preventive modalities. Currently, NIAID funds more than 300 HIV/AIDS clinical trials in more than 50 countries at more than 1,000 domestic and international clinical research sites.
    [Show full text]
  • Assessment of Pharmacist's Knowledge and Perception Toward
    pharmacy Article Assessment of Pharmacist’s Knowledge and Perception toward 3D Printing Technology as a Dispensing Method for Personalized Medicine and the Readiness for Implementation Mohammed S. Algahtani Department of Pharmaceutics, College of Pharmacy, Najran University, Najran 1988, Saudi Arabia; [email protected]; Tel.: +966-17-458-7200 Abstract: The main user of three dimensional (3D) printing for drug dispensing will be the hospital pharmacist. Yet despite the tremendous amount of research and industrial initiatives, there is no evaluation of the pharmacist’s knowledge and opinion of this technology. The present study aimed to assess knowledge and attitude among pharmacists about 3D printing technology as an innovative dispensing method for personalized medicine and the barriers to implementation in Saudi Arabia. We found that 53% of participants were aware of 3D printing technology in general, but only 14–16% of pharmacists were aware of the specific application of 3D printing in drug dispensing. Participants showed a positive perception regarding the concept of personalized medicine and that 3D printing could provide a promising solution to formulate and dispense personalized medicine in the pharmacy. It was also found that 67% of pharmacists were encouraged to adopt this new technology for drug dispensing, reflecting their willingness to learn new innovations. However, the technology cost, regulation, and the shortage of practicing pharmacists were also reported as the top barriers for Citation: Algahtani, M.S. Assessment of Pharmacist’s implementation. Facilitating the implementation of this technology in the pharmacy practice will Knowledge and Perception toward require a strategic plan in which pharmacists collaborate with regulatory bodies and 3D printing 3D Printing Technology as a engineers to overcome challenges and barriers to implement such promising technology.
    [Show full text]
  • Page 1 of 6 Science/AAAS | Table of Contents: 18 December 2009; 326
    Science/AAAS | Table of Contents: 18 December 2009; 326 (5960) Page 1 of 6 Enter Search Term ADVANCED AAAS.ORG FEEDBACK HELP LIBRARIANS Science Magazine NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY ALERTS | ACCESS RIGHTS | MY ACCOUNT | SIGN IN Science Home Current Issue Previous Issues Science Express Science Products My Science About the Journal Home > Science Magazine > Issue Archive > 2009 > 18 December 2009 ADVERTISEMENT 18 DECEMBER 2009 VOL 326, ISSUE 5960, PAGES 1577-1744 Special Issue Letters Brevia This Week in Science Books et al. Research Articles Editorial Education Forum Reports Editors' Choice Perspectives News of the Week Association Affairs News Focus Front and Back Matter from the Print Issue [PDF] About the Cover ADVERTISEMENT Author Index Subject Index Set E-Mail Alerts Order an Issue/Article RSS Feeds Search the Journal Issue Highlights Enter Keyword 2009 Breakthrough of the Year Silent Hate This issue only Universal Few-Body Binding Home is Where the Hearth Is Special Issue For all checked items Breakthrough of the Year Video: Ardipithecus ramidus Science 18 December 2009: 1598. A video introduction to the year's top science story, featuring scientists C. Owen Lovejoy, Tim White, Giday WoldeGabriel, Yohannes Haile-Selassie, Science contributing correspondent Ann Gibbons, and commentary by paleoanthropologist Andrew Hill. Summary » Full Text » News BREAKTHROUGH OF THE YEAR Ardipithecus ramidus Ann Gibbons Science 18 December 2009: 1598-1599. A rare 4.4-million-year-old skeleton has drawn back the curtain of time to reveal the surprising body plan and ecology of our earliest ancestors. Summary » Full Text » PDF » BREAKTHROUGH OF THE YEAR The Runners-Up The News Staff Science 18 December 2009: 1600-1607.
    [Show full text]
  • Evaluating the Efficiency of Grnas in CRISPR/Cas9 Mediated Genome
    International Journal of Molecular Sciences Article Evaluating the Efficiency of gRNAs in CRISPR/Cas9 Mediated Genome Editing in Poplars Tobias Bruegmann * , Khira Deecke and Matthias Fladung * Thuenen Institute of Forest Genetics, Sieker Landstrasse 2, D-22927 Grosshansdorf, Germany * Correspondence: [email protected] (T.B.); matthias.fl[email protected] (M.F.) Received: 21 June 2019; Accepted: 21 July 2019; Published: 24 July 2019 Abstract: CRISPR/Cas9 has become one of the most promising techniques for genome editing in plants and works very well in poplars with an Agrobacterium-mediated transformation system. We selected twelve genes, including SOC1, FUL, and their paralogous genes, four NFP-like genes and TOZ19 for three different research topics. The gRNAs were designed for editing, and, together with a constitutively expressed Cas9 nuclease, transferred either into the poplar hybrid Populus canescens × or into P. tremula. The regenerated lines showed different types of editing and revealed several homozygous editing events which are of special interest in perennial species because of limited back-cross ability. Through a time series, we could show that despite the constitutive expression of the Cas9 nuclease, no secondary editing of the target region occurred. Thus, constitutive Cas9 expression does not seem to pose any risk to additional editing events. Based on various criteria, we obtained evidence for a relationship between the structure of gRNA and the efficiency of gene editing. In particular, the GC content, purine residues in the gRNA end, and the free accessibility of the seed region seemed to be highly important for genome editing in poplars. Based on our findings on nine different poplar genes, efficient gRNAs can be designed for future efficient editing applications in poplars.
    [Show full text]
  • Paving the Way for Personalized Medicine
    OCTOBER 2013 Paving the Way for Personalized Medicine FDA’s Role in a New Era of Medical Product Development U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES U.S. FOOD AND DRUG ADMINISTRATION Paving the Way for Personalized Medicine: FDA’s Role in a New Era of Medical Product Development COMMISSIONER’S MESSAGE 2 I. INTRODUCTION 3 II. PERSONALIZED MEDICINE FROM A REGULATORY PERSPECTIVE 5 1. DEFINING PERSONALIZED MEDICINE 5 2. FDA’S UNIQUE ROLE AND RESPONSIBILITIES IN PERSONALIZED MEDICINE 11 III. DRIVING TOWARD AND RESPONDING TO SCIENTIFIC ADVANCES 14 1. BUILDING THE INFRASTRUCTURE TO SUPPORT PERSONALIZED MEDICINE 16 2. RECENT ORGANIZATIONAL EFFORTS 20 IV. DEFINING AND CLARIFYING REGULATORY PATHWAYS AND POLICIES 23 1. ENSURING THE AVAILABILITY OF SAFE AND EFFECTIVE DIAGNOSTICS 29 2. PRODUCT INTERDEPENDENCY 32 3. PRODUCT LABELING 36 4. POST-MARKET SURVEILLANCE 40 V. ADVANCING REGULATORY SCIENCE IN SUPPORT OF PERSONALIZED MEDICINE 42 1. DEVELOPING REGULATORY STANDARDS, RESEARCH METHODS, AND TOOLS 42 2. CONDUCTING AND COLLABORATING IN RESEARCH 47 VI. A NEW ERA OF MEDICAL PRODUCT DEVELOPMENT: OPPORTUNITIES AND CHALLENGES AHEAD 54 GLOSSARY OF TERMS 58 ENDNOTES 60 ver the past few years, a number of products that signal a new era of medical product development have entered the market or come on the horizon. In just the last two years, the FDA approved four cancer drugs for use in patients whose tumors have specific genetic characteristics that Oare identified by a companion diagnostic test. Last year, FDA approved a new therapy for use in certain cystic fibrosis patients with a specific genetic mutation. Earlier this year, three-dimensional (3D) printing was used to create a bioresorbable tracheal splint for treating a critically-ill infant.
    [Show full text]
  • Introduction to Genomic Medicine
    Introduction to Genomic Medicine What is genomic medicine? There are more than 7 billion people on our planet, each a massive collection of about 100 trillion cells. How do these cells know what to do? What tells them to work together to keep your brain thinking, heart pumping, and hair growing? The answer lies in a long, winding molecule called deoxyribonucleic acid, or DNA. DNA could be referred to as an instruction manual on how cells work as it contains genes that carry instructions needed to build and maintain the many different types of cells that make us unique. Researchers call this complete set of DNA instructions a “genome.” Our health is determined by our inherited or acquired genetic differences combined with our lifestyles and other environmental factors. Although greater than 99.9% of a DNA sequence is identical from person to person, the last 0.1% helps to explain these differences. Different people may have small variations in specific genes, and some people may have genes that others do not. These may increase susceptibility to a specific disease or provide protection from that illness. By combining and analysing information about our genome, with clinical and diagnostic information and then comparing that with data from others, patterns can be identified. Together this information can help to determine our individual risk of developing disease, detect illness earlier, provide accurate diagnosis, support disease monitoring and determine the most effective interventions to help improve our health, either by the use of medication or lifestyle choices. Genomic medicine describes these efforts. Genomic medicine sometimes also known as personalized medicine is a move away from a ‘one size fits all’ approach to the treatment and care of patients with a particular condition, to one which uses new approaches to better manage patients’ health and target therapies to achieve the best outcomes in the management of a patient’s disease or predisposition to disease.
    [Show full text]
  • Definition of Personalized Medicine and Targeted Therapies
    Journal of Personalized Medicine Article Definition of Personalized Medicine and Targeted Therapies: Does Medical Familiarity Matter? Valentyn Fournier 1,* , Thomas Prebet 2, Alexandra Dormal 2, Maïté Brunel 1, Robin Cremer 3 and Loris Schiaratura 1 1 University of Lille, ULR 4072—PSITEC—Psychologie: Interactions, Temps, Emotions, Cognition, F-59000 Lille, France; [email protected] (M.B.); [email protected] (L.S.) 2 Yale Cancer Center, Yale University, 333 Cedar Street, New Haven, CT 06520, USA; [email protected] (T.P.); [email protected] (A.D.) 3 Espace éthique régional des Hauts-de-France, Centre Hospitalier Universitaire de Lille, F-59037 Lille, France; [email protected] * Correspondence: [email protected] Abstract: Personalized medicine (PM) is increasingly becoming a topic of discussion in public health policies and media. However, there is no consensus among definitions of PM in the scientific literature and the terms used to designate it, with some definitions emphasizing patient-centered aspects and others emphasizing biomedical aspects. Furthermore, terms used to refer to PM (e.g., “pharmacogenomics” or, more often, “targeted therapies”) are diverse and differently used. To our knowledge, no study has apprehended the differences of definition and attitudes toward personalized medicine and targeted therapies according to level of familiarity with the medical field. Our cohort included 349 French students from three different academic fields, which modulated their familiarity level with the medical field. They were asked to associate words either to “personalized medicine” or “target therapies”. Then, they were asked to give an emotional valence to their associations.
    [Show full text]